Company profile

Coya Therapeutics, Inc.

Pipeline5 assets

COYA 302COYA 302 / Treg enhancement; T effector and macrophage depletion / Treg-enhancing/T effector and macrophage-depleting biologic combination; low-dose IL-2 + CTLA4-Ig / Neurodegenerative diseases
Amyotrophic lateral sclerosisPhase 2Fast Track; ALSTARS Phase 2 enrollingUSCanadaFrontotemporal dementiaIND acceptedactiveUSAlzheimer's diseasePreclinical/POCactive
COYA 301COYA 301 / IL-2; Treg function and expansion / Proprietary low-dose IL-2 biologic / Neurodegenerative diseases
Alzheimer's diseaseIND-enablingactive
COYA 303COYA 303 / IL-2; GLP-1 receptor / COYA 301 + GLP-1 receptor agonist combination / Inflammatory diseases
UndisclosedDiscoveryactive
COYA 201COYA 201 / Allogeneic Treg-derived exosomes / Undisclosed
UndisclosedPreclinicalactive
COYA 206COYA 206 / Antigen-directed allogeneic Treg-derived exosomes / Undisclosed
UndisclosedPreclinicalactive

Latest news13 items

May 27, 2026

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

May 12, 2026

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Apr 9, 2026

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Apr 2, 2026

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Mar 18, 2026

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Mar 16, 2026

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Feb 10, 2026

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Jan 30, 2026

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 20, 2026

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 8, 2026

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 5, 2026

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Dec 23, 2025

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, Inc. • Endpoint Arena